Alligator Bioscience enters into research and option agreement with
BioInvent to jointly develop Ant
(Thomson Reuters ONE) - Lund, Sweden- September 17, 2009 - Alligator Bioscience AB todayannounced a research and option agreement with BioInventInternational AB to co-develop an antibody-based drug for oncologyindications.This collaboration combines the strengths of both companies'technologies to develop a next generation immunotherapeutic treatmentthat could provide systemic anti-cancer effect and immunity, withminimal systemic side effects for the benefit of cancer patients.Dr Gun-Britt Fransson, Chief Executive Officer of AlligatorBioscience, commented: "We are very pleased to work with BioInvent, acompany with proven success in developing antibody-based drugs, andwe believe that Alligator Biosciences technology and know-how willadd a substantial value and success to this joint program. Further,it also confirms that Alligator Biosciences technology is valuableand needed for the development of next generation antibody baseddrugs". According to the terms, the parties will after an initialresearch phase share costs and revenues equally.Alligator Bioscience AB is a privately owned drug discovery anddevelopment company focused on optimization of biopharmaceuticalsusing it's proprietary protein optimization technology FIND®(Fragment INduced Diversity). FIND® technology can redesignvirtually any characteristics of a protein that can be translatedinto significant clinical benefits, including higher efficacy andpotency, improved safety profile and decreased immunogenicity. Thetechnology offers unique opportunities to discover novel protein drugcandidates as well as creating second generation biopharmaceuticals.Founded in 2001 in Lund, Sweden, Alligator Bioscience hassuccessfully collaborated with several companies in thepharmaceutical and biotech industry, improving customers' proteinsand helping them to build more competitive pipelines.Contact:Dr Gun-Britt Fransson, CEOAlligator Bioscience ABScheelevägen 19ASE-223 70 Lund, SwedenTel: +46 (0)46-2864280Fax: +46 (0)46-2864290www.alligatorbioscience.comhttp://hugin.info/134803/R/1342068/321121.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 17.09.2009 - 17:08 Uhr
Sprache: Deutsch
News-ID 5939
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alligator Bioscience enters into research and option agreement with
BioInvent to jointly develop Ant"
steht unter der journalistisch-redaktionellen Verantwortung von
Alligator Bioscience AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
